The cost-effectiveness of sibutramine in non-diabetic obese patients: Evidence from four Western countries

Obesity Reviews

Volumn 8, Issue 4, 2007, Pages 363-371

  Ara, R ^a   Brennan, A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Analysis; Cost effectiveness; Obesity; Sibutramine

Indexed keywords

PLACEBO; SIBUTRAMINE;

ARTICLE; BODY MASS; CLINICAL TRIAL; COST; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIET; DRUG DOSE TITRATION; EXERCISE; GERMANY; HUMAN; ISCHEMIC HEART DISEASE; MONITORING; OBESITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SWITZERLAND; WEIGHT REDUCTION;

ADULT; AGE DISTRIBUTION; AGED; APPETITE DEPRESSANTS; COHORT STUDIES; CORONARY DISEASE; COST-BENEFIT ANALYSIS; CYCLOBUTANES; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; FINLAND; GERMANY; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; OBESITY; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SWITZERLAND;

EID: 34250618388     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2007.00352.x     Document Type: Article

References (36)

1. Obesity in Europe: the International Obesity Task Force and European Association for the Study of Obesity. Case for Action. [WWW document]. URL http://www.iotf.org/media/euobesity.pdf (accessed 23 May 2006).
2. Weinstein AR, Sesso HD, Lee IM, Cook NR, Manson JE, Buring JE, Gaziano JM. Relationship of physical activity vs body mass index with type 2 diabetes in women. JAMA 2004 292 : 1188 1194.
3. Hu G, Barengo NC, Tuomilehto J, Lakka TA. Relationship of physical activity and body mass index to the risk of hypertension: a prospective study in Finland. Hypertension 2004 43 : 25 30.
4. Gostynski M, Gutzwiller F, Kuulasmaa K, Doring A, Ferrario M, Grafnetter D, Pajak A. Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project. Int J Obes Relat Metab Disord 2004 28 : 1082 1090.
5. Hu G, Tuomilehto J, Silventoinen K, Barengo NC, Peltonen M, Jousilahti P. The effects of physical activity and body mass index on cardiovascular, cancer and all-cause mortality among 47 2 12 middle-aged Finnish men and women. Int J Obes 2005 29 : 894 902.
6. Klein S, Burke LE, Bray GA, Blair S. Clinical implications of obesity with specific focus on cardiovascular disease. Circulation 2004 110 : 2952 2967.
7. Association for the Study of Obesity. The Composition of the Human Body. [WWW document]. URL http://www.aso.org.uk/portal.asp?oricmid=156&orictype= header&targetcell=3,0&targetwidth=4&functionname= aso_oric#oricarticle (accessed 23 May 2006).
8. National Institute of Clinical Excellence. Final Scope: Obesity. [WWW document]. URL http://www.nice.org.uk/page.aspx?o=211305 (accessed 23 May 2006).
9. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004 24 : 9 19.
10. Brennan A, Ara R, Stertz R., Matiba B, Bergmann R. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Eur J Health Econ 2006 (in press).
11. Hauner H, Meier M, Wendland G, Lauterbach K. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study Group. Exp Clin Endocrinol Diabetes 2004 112 : 201 207.
12. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991 83 : 356 362.
13. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983 67 : 968 977.
14. Colditz GA, Walter MBBS, Wilcott C, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes in women. Ann Intern Med 1995 122 : 481 486.
15. Sjostrom D, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999 7 : 477 484.
16. Heitman BL, Garby L. Patterns of long-term weight changes in overweight developing Danish men and women aged between 30 and 60 years. Int J Obes 1999 23 : 1074 1078.
17. James WP, Astrup A, Finer N, Hiloted J, Kopelman P, Rossner S, Sarts WH, Van Gaal LF. On behalf of the STORM Study Group (Sibutramine Trial of Obesity Reduction and Maintenance). Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000 356 : 2119 2125.
18. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001 50 : 505 512.
19. Reductil, Summary of Product Characteristics. [WWW document]. URL http://emc.medicines.org.uk (accessed January 2005).
20. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol 1998 51 : 1115 1129.
21. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998 316 : 736 741.
22. Aromaa A, Koskinen S (eds). Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Hakapaino Oy : Helsinki, 2004.
23. Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HA. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. Heart 1998 80 : 40 44.
24. Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA on behalf of the Canadian Collaborative Cardiac Assessment Group. Health-related quality of life with coronary heart disease prevention and treatment. J Clin Epidemiol 2001 54 : 1011 1018.
25. Clarke P, Gray A. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002 22 : 340 349.
26. Scholze J. Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters. Dtsch Med Wochenschr 2002 127 : 606 610.
27. Kettula M. Sydäninfarktipotilaan hoitoketjun toimivuus ja hoitokustannusten potilaskohtainen jakautuminen Etelä-Pohjanmaalla. Acta Universitatis Tamperensis 823, University of Tampere : Tampere, 2001.
28. Hujanen T. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2001. Stakes Aiheita 1/2003. National Public Health Institute. The Health 2000 data on file http://www.ktl.fi/health2000/ (accessed March 2004).
29. Kangas T. Diabeetikkojen terveyspalvelut ja niiden kustannukset. KELA, Sosiaali- ja terveysturvan tutkimuksia 67 : Helsinki, 2002.
30. Klever-Deichert G, Hinzpeter B, Hunsche E, Lauterbach KW. Costs of coronary heart diseases over the remaining life time in coronary heart disease cases - an analysis of the current status of coronary heart disease cases in Germany from the social perspective. Z Kardiol 1999 88 : 991 1000.
31. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002 45 : S5 12.
32. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Med 2003 20 : 442 450.
33. Unknown. UKPDS40. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes. UKPDS Study Group. BMJ 1998 317 : 720 726.
34. Gray A, Raikou M, McGurire A, Fenn P, Stevens R, Cull C, Stratton IM, Adler AI, Holman RR, Turner RC. UKPDS41. A cost effectiveness analysis of an intensive blood glucose policy in Type 2 diabetic patients. BMJ 2000 320 : 1373 1378.
35. Colagiuri S, Cull CA, Holman RR, UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UKPDS Study 61 2002 25 : 1410 1417.
36. James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000 320 : 1627 1631.